| An update on diagnostic and prognostic biomarkers for traumatic brain injury |
47 |
| Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective |
30 |
| The challenge of diagnostic metagenomics |
24 |
| Label-free plasmonic biosensors for point-of-care diagnostics: a review |
23 |
| Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma |
23 |
| Serum, plasma and saliva biomarkers for head and neck cancer |
18 |
| The potential of circulating cell-free RNA as a cancer biomarker: challenges and opportunities |
18 |
| miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers |
16 |
| Liquid biopsy tracking of lung tumor evolutions over time |
14 |
| Novel applications for serum procalcitonin testing in clinical practice |
13 |
| A review of validated biomarkers obtained through metabolomics |
13 |
| The potential of tumor-derived exosomes for noninvasive cancer monitoring: an update |
12 |
| The breast tumor microenvironment: role in cancer development, progression and response to therapy |
12 |
| PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy |
11 |
| An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer |
11 |
| Rapid and simple molecular tests for the detection of respiratory syncytial virus: a review |
11 |
| Digital microfluidics comes of age: high-throughput screening to bedside diagnostic testing for genetic disorders in newborns |
10 |
| Localized surface plasmon resonance based biosensing |
10 |
| Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update |
10 |
| The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker |
10 |
| Recent advances in the molecular diagnosis of mucormycosis |
10 |
| MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury |
10 |
| Testing for genetic contributions to infertility: potential clinical impact |
9 |
| Current and future molecular diagnostics of gastric cancer |
8 |
| The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine |
8 |
| Molecular diagnosis of coenzyme Q(10) deficiency: an update |
8 |
| Blood biomarkers and treatment response in major depression |
8 |
| Advances in prognostic markers for colorectal cancer |
8 |
| ClonoSEQ assay for the detection of lymphoid malignancies |
8 |
| Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation |
8 |
| Emerging methodologies for pathogen identification in bloodstream infections: an update |
8 |
| CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer |
8 |
| Circulating exosomal miRNAs: clinical significance in human cancers |
7 |
| Point-of-care diagnostics for respiratory viral infections |
7 |
| Loop-mediated isothermal amplification assay as a point-of-care diagnostic tool for Vibrio parahaemolyticus: recent developments and improvements |
7 |
| Emerging proteomic biomarkers of X-linked muscular dystrophy |
7 |
| Novel applications of array comparative genomic hybridization in molecular diagnostics |
7 |
| The fractal dimension of chromatin - a potential molecular marker for carcinogenesis, tumor progression and prognosis |
7 |
| Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis-an update |
7 |
| Next-generation sequencing and the impact on prenatal diagnosis |
7 |
| Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test |
6 |
| The host response as a tool for infectious disease diagnosis and management |
6 |
| The clinical use of IDH1 and IDH2 mutations in gliomas |
6 |
| Clinical utility of microRNAs in renal cell carcinoma: current evidence and future perspectives |
6 |
| Application of NanoString technologies in companion diagnostic development |
6 |
| ESR1 mutations: a new biomarker in breast cancer |
6 |
| From next-generation sequencing to targeted treatment of non-acquired epilepsies |
6 |
| Recent advances in molecular testing to improve early diagnosis in children with mucopolysaccharidoses |
6 |
| What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer? |
6 |
| Profile of GenMark's ePlex (R) blood culture identification fungal pathogen panel |
6 |
